EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Select gene mutations associated with survival outcomes in ER ‐positive ERBB2 ‐negative early‐stage invasive breast cancer: A single‐institutional tissue bank study

Victor C Kok iD, To-Yu Huang iD, Yi-Chiung Hsu iD, Yuan-Ching Chang, Po-Sheng Yang iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Victor C Kok und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Kuang Tien General Hospital Cancer Center, Taichung, Taiwan. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Mutation, Receptors, Estrogen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MacKay Memorial Hospital, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The prognostic capability of targeted sequencing of primary tumors in patients with estrogen receptor‐positive, human epidermal growth factor receptor‐2‐negative early‐stage invasive breast cancer (EBC) in a real‐world setting is uncertain. Therefore, we aimed to determine the correlation between a 22‐gene mutational profile and long‐term survival outcomes in patients with ER+/ERBB2‐ EBC. Patients and Methods A total of 73 women diagnosed with ER+/ERBB2‐ EBC between January 10, 2004, and June 2, 2008, were followed up until December 31, 2022. Univariate and multivariate Cox models were constructed to plot the relapse‐free survival (RFS) and overall survival (OS). The log‐rank test derived p ‐value was obtained. For external validation, we performed a survival analysis of 1163 comparable patients retrieved from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset.

Results

At follow‐up, 16 (21.9%) patients had relapsed, while 21 (nearly 29%) harbored mutant genes. Thirty‐three missense mutations were detected in 14 genes. The median ages were 51 and 46 years in patients with and without mutations, respectively. Patients with any mutation had a 1.85‐fold higher risk of relapse (hazard ratio [HR]: 1.85, 95% confidence interval [CI]: 0.60–5.69) compared to those without any mutation. Patients who harbored any of the six genes ( MAP2K4, FGFR3, APC, KIT, RB1 , and PTEN ) had a nearly 6‐fold increase in the risk of relapse (HR: 5.82, 95% CI: 1.31–18.56; p = 0.0069). Multivariate Cox models revealed that the adjusted HR for RFS and OS were 6.67 (95% CI: 1.32–27.57) and 8.31 ( p = 0.0443), respectively. METABRIC analysis also demonstrated a trend to significantly worse RFS ( p = 0.0576) in the subcohort grouped by having a mutation in any of the six genes.

Conclusions

Our single‐institution tissue bank study of Taiwanese women with ER+/ERBB2‐ EBC suggests that a novel combination of six gene mutations might have prognostic capability for survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesMutationReceptors, EstrogenHumansFemaleMiddle AgedPrognosisAdultNeoplasm StagingBiomarkers, TumorAgedNeoplasm Invasiveness

Stichwörter der Autor:innen

ER+/HER2‐multigene mutational panelprognosticationrelapse‐free survivaltargeted sequencingtissue bank

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology, Kuang Tien General Hospital Cancer Center, Taichung, Taiwan.
  • Department of Medical Research, MacKay Memorial Hospital, New Taipei, Taiwan.
  • Department of Biomedical Sciences and Engineering, National Central University, Taoyuan, Taiwan.
  • Center for Astronautical Physics and Engineering, National Central University, Taoyuan, Taiwan.
  • Department of General Surgery, MacKay Memorial Hospital, Taipei, Taiwan.
  • Department of Medicine, Mackay Medical College, New Taipei, Taiwan.

ORCID-Profile: Victor C Kok, To-Yu Huang, Yi-Chiung Hsu, Po-Sheng Yang

Förderung

  • MacKay Memorial Hospital
  • National Science and Technology Council

Zitieren

APA

Kok, V. C., Huang, T. Y., Hsu, Y. C., Chang, Y. C., & Yang, P. S. (2024). Select gene mutations associated with survival outcomes in ER ‐positive ERBB2 ‐negative early‐stage invasive breast cancer: A single‐institutional tissue bank study. Cancer Medicine. https://doi.org/10.1002/cam4.70035

Vancouver

Kok VC, Huang TY, Hsu YC, Chang YC, Yang PS. Select gene mutations associated with survival outcomes in ER ‐positive ERBB2 ‐negative early‐stage invasive breast cancer: A single‐institutional tissue bank study. Cancer Medicine. 2024. doi:10.1002/cam4.70035

BibTeX
@article{Kok2024,
  author = {Kok, Victor C and Huang, To-Yu and Hsu, Yi-Chiung and Chang, Yuan-Ching and Yang, Po-Sheng},
  title = {Select gene mutations associated with survival outcomes in ER ‐positive ERBB2 ‐negative early‐stage invasive breast cancer: A single‐institutional tissue bank study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70035}
}
Kostenlos starten →